Grifols has achieved a net profit of €390 million by September, a 28.4% increase, and has announced a dividend of €0.15 per share. The company has also reduced its debt.
The pharmaceutical company Grifols presented its results for September on November 2, reporting a net profit of €390 million, which is 28.4% more than in the same period of 2025. According to information published by Estrella Digital, the company has also reduced its debt and announced a dividend of €0.15 per share.
According to the statement sent to the National Securities Market Commission (CNMV), accumulated revenues reached €5.614 billion, a 4.6% increase at constant exchange rates. In the third quarter, revenue was €2.040 billion, an 8.4% increase, and net profit rose 27.9% to €162 million.
The presentation took place after the close of the Spanish stock market, during which shares exceeded €11.20. The company is also listed on the Nasdaq in New York under the symbol GRFS, and has confirmed that it maintains its financial targets for 2026.
The company has not detailed in the consulted documentation the payment date of the dividend or the schedule for entitlement to it.
Regarding debt, Grifols reports its net leverage at 3.98 times as of the end of September, down from 4.2 times a year earlier and 5.1 times in 2024. The company has liquidity of €2.14 billion and has completed the refinancing of obligations due in 2027, meaning it has no significant maturities until the fourth quarter of 2028.
Free cash flow before mergers, acquisitions, and dividends was €298 million from January to September, €110 million more than in the same period of 2025. Of this figure, €208 million corresponds to the third quarter alone.
The Biopharma business remains the main driver. Its revenues grew 7.1% at constant exchange rates by September, accelerating to 10.3% in the third quarter. Immunoglobulins rose 12.3%, and subcutaneous treatments increased by 40.3% in the quarter.
The CEO, Nacho Abia, stated in the announcement:
“The results of the third quarter reflect the sustained execution of our plan, with growth in our main businesses translating into greater profitability and cash generation.”
The company also acknowledges a decline in albumin in China, where revenues have fallen 13.9% so far this year.
Grifols is also considering a potential stock market listing of a minority stake in its Biopharma business in the United States, an operation that is still under evaluation. Additionally, the pharmaceutical company has confirmed that its project in Egypt already has 18 plasma donation centres and aims to reach 20 in the first quarter of 2027.
You may also like
